Background: Atopic dermatitis (AD) has a complicated pathogenesis and its clinical features vary greatly among patients. Although many clinical parameters have been reported, it remains difficult to evaluate AD skin conditions adequately. Objective: To support better evaluation of AD patients, we attempted to develop a new, objective and noninvasive method that assesses skin condition in AD using biochemical markers in the skin’s horny layer (HL). Methods: Thirty-six patients with AD, 8 with psoriasis and 16 healthy volunteers were recruited. HL samples were obtained by tape stripping from involved and uninvolved skin of the forearms. Expression levels of 6 proteins in the HL [fatty acid-binding protein-5 (FABP-5), squamous cell carcinoma antigens 2 (SCCA2), α-enolase, annexin II, apolipoprotein A-I and albumin] were analyzed by immunoblotting and compared with clinical data. Results: The 6 proteins were detected at a high level in AD skin lesions, but scarcely in the normal controls. FABP-5 showed correlation with the local severity of the involved skin. Annexin II, apoprotein A-I and albumin showed correlation with the severity of specific eruptions. SCCA2 correlated significantly with total serum IgE level. Albumin levels in the uninvolved skin of AD patients showed significant correlation with the local severity in the involved skin of the same patient and with the trans-epidermal water loss. Albumin levels in psoriatic skin were very low, even with scratch marks, compared to those in AD skin. Conclusion: FABP-5, albumin and some other proteins in HL seem to be useful as biomarkers to evaluate inflammation and skin barrier conditions in AD patients.

Keywords:
Atopic dermatitis, Albumin, Biomarkers, Fatty acid-binding protein 5, Horny layer
1.
Leung DY, Boguniewicz M, Howell MD, Nomura I, Hamid QA: New insights into atopic dermatitis. J Clin Invest 2004;113:651–657.
2.
Kay AB, Ying S, Varney V, Gaga M, Durham SR, Moqbel R, Wardlaw AJ, Hamid Q: Messenger RNA expression of the cytokine gene cluster, interleukin 3 (IL-3), IL-4, IL-5, and granulocyte/macrophage colony-stimulating factor, in allergen-induced late-phase cutaneous reactions in atopic subjects. J Exp Med 1991;173:775–778.
3.
Hamid Q, Boguniewicz M, Leung DY: Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis. J Clin Invest 1994;94:870–876.
4.
Hamid Q, Naseer T, Minshall EM, Song YL, Boguniewicz M, Leung DY: In vivo expression of IL-12 and IL-13 in atopic dermatitis. J Allergy Clin Immunol 1996;98:225–231.
5.
Grewe M, Bruijnzeel-Koomen CA, Schöpf E, Thepen T, Langeveld-Wildschut AG, Ruzicka T, Krutmann J: A role for Th1 and Th2 cells in the immunopathogenesis of atopic dermatitis. Immunol Today 1998;19:359–361.
6.
Grewe M, Gyufko K, Schöpf E, Krutmann J: Lesional expression of interferon-gamma in atopic eczema. Lancet 1994;343:25–26.
7.
Sator PG, Schmidt JB, Hönigsmann H: Comparison of epidermal hydration and skin surface lipids in healthy individuals and in patients with atopic dermatitis. J Am Acad Dermatol 2003;48:352–358.
8.
Charman C, Williams H: Outcome measures of disease severity in atopic eczema. Arch Dermatol 2000;136:763–769.
9.
Mukai H, Noguchi T, Kamimura K, Nishioka K, Nishiyama S: Significance of elevated serum LDH (lactate dehydrogenase) activity in atopic dermatitis. J Dermatol 1990;17:477–481.
10.
Hanifin J, Rajka G: Diagnostic features of atopic dermatitis. Acta Dermatol Venereol Suppl 1980;92:44–47.
11.
Kunz B, Oranje AP, Labrèze L, Stalder JF, Ring J, Taïeb A: Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology 1997;195:10–19.
12.
Leung DY: Atopic dermatitis: immunobiology and treatment with immune modulators. Clin Exp Immunol 1997;107(suppl 1): 25–30.
13.
Siegenthaler G, Hotz R, Chatellard-Gruaz D, Didierjean L, Hellman U, Saurat JH: Purification and characterization of the human epidermal fatty acid-binding protein: localization during epidermal cell differentiation in vivo and in vitro. Biochem J 1994;302:363–371.
14.
O’Shaughnessy RF, Seery JP, Celis JE, Frischauf A, Watt FM: PA-FABP, a novel marker of human epidermal transit amplifying cells revealed by 2D protein gel electrophoresis and cDNA array hybridisation. FEBS Lett 2000;486:149–154.
15.
Iizuka H, Ishida-Yamamoto A, Honda H: Epidermal remodelling in psoriasis. Br J Dermatol 1996;135:433–438.
16.
Iizuka H, Honda H, Ishida-Yamamoto A: Epidermal remodeling in psoriasis (II): a quantitative analysis of the epidermal architecture. J Invest Dermatol 1997;109:806–810.
17.
Kassam G, Choi KS, Ghuman J, Kang HM, Fitzpatrick SL, Zackson T, Zackson S, Toba M, Shinomiya A, Waisman DM: The role of annexin II tetramer in the activation of plasminogen. J Biol Chem 1998;273:4790–4799.
18.
Pancholi V: Multifunctional alpha-enolase: its role in diseases. Cell Mol Life Sci 2001;58:902–920.
19.
Gitlits VM, Toh BH, Sentry JW: Disease association, origin, and clinical relevance of autoantibodies to the glycolytic enzyme enolase. J Investig Med 2001;49:138–145.
20.
Neuber K, Mähnss B, Hübner C, Gergely H, Weichenthal M: Autoantibodies against CD28 are associated with atopic diseases. Clin Exp Immunol 2006;146:262–269.
21.
Ochs RL, Muro Y, Si Y, Ge H, Chan EK, Tan EM: Autoantibodies to DFS 70 kd/transcription coactivator p75 in atopic dermatitis and other conditions. J Allergy Clin Immunol 2000;105:1211–1220.
22.
Takeda A, Yamamoto T, Nakamura Y, Takahashi T, Hibino T: Squamous cell carcinoma antigen is a potent inhibitor of cysteine proteinase cathepsin L. FEBS Lett 1995;359:78–80.
23.
Schick C, Pemberton PA, Shi GP, Kamachi Y, Cataltepe S, Bartuski AJ, Gornstein ER, Brömme D, Chapman HA, Silverman GA: Cross-class inhibition of the cysteine proteinases cathepsins K, L, and S by the serpin squamous cell carcinoma antigen 1: a kinetic analysis. Biochemistry 1998;37:5258–5266.
24.
Schick C, Kamachi Y, Bartuski AJ, Cataltepe S, Schechter NM, Pemberton PA, Silverman GA: Squamous cell carcinoma antigen 2 is a novel serpin that inhibits the chymotrypsin-like proteinases cathepsin G and mast cell chymase. J Biol Chem 1997;272:1849–1855.
25.
Takeda A, Higuchi D, Takahashi T, Ogo M, Baciu P, Goetinck PF, Hibino T: Overexpression of serpin squamous cell carcinoma antigens in psoriatic skin. J Invest Dermatol 2002;118:147–154.
26.
Mitsuishi K, Nakamura T, Sakata Y, Yuyama N, Arima K, Sugita Y, Suto H, Izuhara K, Ogawa H: The squamous cell carcinoma antigens as relevant biomarkers of atopic dermatitis. Clin Exp Allergy 2005;35:1327–1333.
27.
Sugarman JL, Fluhr JW, Fowler AJ, Bruckner T, Diepgen TL, Williams ML: The objective severity assessment of atopic dermatitis score: an objective measure using permeability barrier function and stratum corneum hydration with computer-assisted estimates for extent of disease. Arch Dermatol 2003;139:1417–1422.
28.
Seidenari S, Giusti G: Objective assessment of the skin of children affected by atopic dermatitis: a study of pH, capacitance and TEWL in eczematous and clinically uninvolved skin. Acta Derm Venereol 1995;75:429–433.
29.
Imokawa G, Abe A, Jin K, Higaki Y, Kawashima M, Hidano A: Decreased level of ceramides in stratum corneum of atopic dermatitis: an etiologic factor in atopic dry skin? J Invest Dermatol 1991;96:523–526.
30.
Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP, Goudie DR, Sandilands A, Campbell LE, Smith FJ, O’Regan GM, Watson RM, Cecil JE, Bale SJ, Compton JG, DiGiovanna JJ, Fleckman P, Lewis-Jones S, Arseculeratne G, Sergeant A, Munro CS, El Houate B, McElreavey K, Halkjaer LB, Bisgaard H, Mukhopadhyay S, McLean WH: Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006;38:441–446.
31.
Nomura T, Sandilands A, Akiyama M, Liao H, Evans AT, Sakai K, Ota M, Sugiura H, Yamamoto K, Sato H, Palmer CN, Smith FJ, McLean WH, Shimizu H: Unique mutations in the filaggrin gene in Japanese patients with ichthyosis vulgaris and atopic dermatitis. J Allergy Clin Immunol 2007;119:434–440.
32.
Smith FJ, Irvine AD, Terron-Kwiatkowski A, Sandilands A, Campbell LE, Zhao Y, Liao H, Evans AT, Goudie DR, Lewis-Jones S, Arseculeratne G, Munro CS, Sergeant A, O’Regan G, Bale SJ, Compton JG, DiGiovanna JJ, Presland RB, Fleckman P, McLean WH: Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris. Nat Genet 2006;38:337–342.
33.
McGrath JA, Uitto J: The filaggrin story: novel insights into skin-barrier function and disease. Trends Mol Med 2008;14:20–27.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.